BioAdaptives

BioAdaptives Debt/Market Cap

The Debt to Market Capitalization Ratio of BioAdaptives (BDPT) as of Oct 27, 2026 is 266.77 %. In the previous year, Debt to Market Capitalization Ratio was 238.09 % — a change of 12.05% (higher).

Debt/Market Cap

266.77 %

YoY

12.05%

Last updated:

Debt to Market Capitalization Ratio of BioAdaptives is 2025 266.77 % . Debt to Market Capitalization Ratio of BioAdaptives was 2024 238.09 % . It decreases by 12.05% higher compared to the previous year.

The BioAdaptives Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
60.94 USD
Jan 1, 2019
256.84 USD
Jan 1, 2020
335.14 USD
Jan 1, 2021
303.14 USD
Jan 1, 2022
272.05 USD
Jan 1, 2023
228.43 USD
Jan 1, 2024
238.09 USD
Jan 1, 2025
266.77 USD
The BioAdaptives Debt/Market Cap history
YEARDebt/Market CapYoY
266.77 %+12.05%
238.09 %+4.23%
228.43 %-16.03%
272.05 %-10.25%
303.14 %-9.55%
335.14 %+30.49%
256.84 %+321.49%
60.94 %—
0.00—
0.00—
0.00-100.00%
23.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Debt to Market Capitalization Ratio of BioAdaptives is 266.77 % in 2025.

Debt to Market Capitalization Ratio of BioAdaptives changed from 238.09 % to 266.77 %, representing a 12.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioAdaptives

All Key Metrics — BioAdaptives